Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

医学 内科学 肿瘤科 胃肠病学 耐火材料(行星科学) 髓系白血病 队列 临床研究阶段 化疗 生物 天体生物学
作者
Jasleen K. Randhawa,Hagop M. Kantarjian,Gautam Borthakur,Philip A. Thompson,M. Konopleva,Naval Daver,Naveen Pemmaraju,Elias Jabbour,Tapan M. Kadia,Zeev Estrov,Abhijit Ramachandran,Jamil Paradela,Michael Andreef,Mark J. Levis,Farhad Ravandi,Jorge E. Cortés
出处
期刊:Blood [Elsevier BV]
卷期号:124 (21): 389-389 被引量:110
标识
DOI:10.1182/blood.v124.21.389.389
摘要

Abstract Introduction FLT3-ITD (Internal tandem duplication) and FLT3-TKD (tyrosine kinase domain, D835) mutations are frequently seen in AML; FLT3-ITDs are associated with inferior survival. Development of FLT3-TKD mutation during FLT3 inhibitor-therapy is seen in up to 22% of patients and associated with FLT3 tyrosine kinase inhibitor (TKI) treatment failure (Cancer 2014). Crenolanib besylate is an orally bioavailable TKI with activity against both FLT3-ITD and FLT3-TKD mutations. We evaluated the clinical efficacy of crenolanib in relapsed/refractory AML pts with activating FLT3 mutations. Methods This was a single center phase II open label study of crenolanib administered at 200 mg/m2/day three times a day continuously in 28 day cycles. FLT3 mutated pts (either FT3-ITD or FLT3-TKD) with primary AML, therapy-related AML and AML following an antecedent hematological disorder were included. Pts were ≥18 years of age with ECOG PS of 0-2. Pts with CNS disease were excluded. Pts relapsing post-allogeneic stem cell transplant could be included if they were >30 days post-transplant. 38 pts enrolled in 2 parallel cohorts of which 34 were evaluable, 13 in cohort A (FLT3 TKI-naïve) and 21 in cohort B (progressed on prior FLT3 TKI). Results Median age was 61 (30 – 87). Patients had undergone a median of 3.5 prior therapies (range 1 – 8); 38% of pts had diploid and 23% complex cytogenetics. Among patients with available information, NPM1 mutation was identified in 62% (10/16) and DNMT3A in 57% (8/14). Median baseline marrow blast % was 58% (7 – 97%). Of cohort B patients, prior therapy was sorafenib in 57%, quizartinib in 14%, PLX3397 in 5% and midostaurin in 10%. 9% and 5% had received 2 and 3 FLT3 TKIs, respectively. 10 enrolled patients had progressed post-transplant (SCT) (3 allogeneic in cohort A; 6 allogeneic, 1 autologous in cohort B). Median duration of study therapy was 9 wks (range 5 – 24), 2 pts remain on study. Reasons for study cessation were disease progression in 66%, no response in 16%, toxicity in 6%, clinical deterioration due to other co-morbidities in 6%, 3% lost to follow up and 3% to receive SCT. At a median follow up of 14 weeks (wks), ORR was 47%: 12% achieved complete response with incomplete count recovery (CRi), 32% hematological improvement (Hi) (85% of them with >50% decrease in blast count) and 3% morphologic leukemia-free state (MLFS). 21% had progressive disease and 32% no response. The median event-free survival (EFS) was 8 wks and overall survival (OS) was 19 wks for the whole cohort. The response by cohort was: Table FLT3 TKI naïve Prior FLT3 Therapy Response % CRi 23 5 MLFS 8 0 Hi 31 33 NR 31 33 PD 8 29 Median OS 55 wks 13 wks (p=0.027) Median EFS 13 wks 7 wks (p<0.001) Pts achieving marrow response (CRi and MLFS) had superior EFS (median 22 wks vs 8 wks for non-responders, p=0.003), with a trend toward superior OS for the marrow responders (median 55 weeks versus 15 wks, p=0.166). 2 of the 4 pts with FLT3-TKD in cohort A responded (CRi, Hi). Among pts with both mutations, 1/1 pt in cohort A achieved CRi and 5/6 pts in cohort B achieved Hi. EFS and OS were not influenced by complex cytogenetics, number of prior therapies or the presence of NPM1 or DNMT3A mutations. OS and EFS were, for patients with ITD (19 wks; 7 wks), D835 (6 wks; 8 wks) or both FLT3 mutations (12 wks; 9 wks), p=0.908; 0.391 respectively. The main grade 3 toxicities were GI side effects (abdominal pain and nausea). There was no death attributed to treatment related toxicity. Conclusions Crenolanib is a well-tolerated FLT3 TKI with clinical efficacy in heavily pre-treated, relapsed/refractory FLT3 mutated AML patients. The superior results in FLT3 inhibitor-naïve patients suggests that on-target FLT3 inhibition is likely primarily responsible for drug efficacy. Combination therapy (e.g., with chemotherapy or hypomethylating agents) could potentially provide additive efficacy in both treatment-naïve and relapsed/refractory pts. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助Xw采纳,获得10
刚刚
1秒前
1秒前
别闹闹发布了新的文献求助10
4秒前
幸运星发布了新的文献求助10
4秒前
CipherSage应助mark采纳,获得10
6秒前
pluto应助从容的香菇采纳,获得10
6秒前
科研通AI5应助cccyq采纳,获得10
7秒前
科研狗完成签到,获得积分10
9秒前
英俊的铭应助gs19960828采纳,获得10
10秒前
MrTStar完成签到 ,获得积分10
12秒前
淡定的惜完成签到,获得积分20
15秒前
完美世界应助fengliurencai采纳,获得10
20秒前
思源应助大面包采纳,获得10
21秒前
sandra完成签到 ,获得积分10
22秒前
iris601完成签到,获得积分10
24秒前
时笙发布了新的文献求助30
26秒前
温柔的迎荷完成签到,获得积分10
28秒前
量子星尘发布了新的文献求助10
30秒前
31秒前
31秒前
传奇3应助快乐一江采纳,获得10
32秒前
传统的纸飞机完成签到 ,获得积分10
32秒前
32秒前
32秒前
王子安应助lilila666采纳,获得10
34秒前
大面包发布了新的文献求助10
35秒前
情怀应助漫山采纳,获得10
36秒前
zzz完成签到,获得积分10
37秒前
gs19960828发布了新的文献求助10
38秒前
幸福大白发布了新的文献求助30
38秒前
脑洞疼应助jbhb采纳,获得10
42秒前
42秒前
gs19960828完成签到,获得积分10
43秒前
Younglee完成签到,获得积分10
47秒前
47秒前
xiaoxuan完成签到,获得积分10
48秒前
49秒前
Garnieta完成签到,获得积分10
50秒前
彤光赫显发布了新的文献求助10
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174